CD8A and neoplasm: Notably, PYGO2, UBQLN4, and ANXA1 have been associated with responsiveness to tumor immune checkpoint blockade (ICB) therapy [25–27], while B4GAL and MDM2 are implicated in regulating CD8 + T cell function and tumor growth [28, 29].